Want to see IN:ROSSARI full AI Analyst Report?

Rossari Biotech Ltd (ROSSARI) Price & Analysis

2 Followers

ROSSARI Stock Chart & Stats

₹583.95

₹39.25(5.10%)

At close: Jan 08 4:00 PM EST

₹583.95

₹39.25(5.10%)

Day’s Range― - ―

52-Week Range₹372.90 - ₹690.90

Previous CloseN/A

Volume112.05K

Average Volume (3M)4.61K

Market Cap

₹23.11B

Enterprise Value₹24.03K

Total Cash (Recent Filing)₹1.15B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)15.7

Beta1.12

Next Earnings

Oct 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.12%

Share Statistics

EPS (TTM)27.22

Shares Outstanding55,394,115

10 Day Avg. Volume3,567

30 Day Avg. Volume4,613

Financial Highlights & Ratios

PEG Ratio1.51

Price to Book (P/B)1.57

Price to Sales (P/S)0.87

P/FCF Ratio-9.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)26.7

Revenue Forecast (FY)₹26.52B

Bulls Say, Bears Say

Bulls Say

Steady Revenue GrowthSustained revenue expansion indicates continued demand for Rossari’s specialty chemical offerings across its served markets. Although growth moderated in 2026, the multi-year trend supports ongoing customer adoption, broader market reach, and a foundation for future operating scale.

Diversified Specialty Chemical ApplicationsExposure to multiple end-use sectors can make the business more resilient than a single-market chemicals supplier. Its application-focused formulations also support cross-selling across customer processes, helping diversify demand and create opportunities for repeat industrial purchases.

Reasonably Healthy Balance SheetModerate leverage and steadily growing equity provide a reasonable capital base for continuing operations and investment. Stable low-teens returns on equity indicate that the company is generating acceptable profitability from shareholder capital, even without recent improvement in returns.

Bears Say

Weak Cash ConversionWeak conversion of reported earnings into operating cash reduces the funds available for reinvestment, debt reduction, and shareholder returns. Persistently negative free cash flow, particularly at the 2026 level, indicates that investment needs or working-capital demands are absorbing substantial liquidity.

Rising Debt BurdenHigher borrowing increases financial obligations and reduces flexibility if cash generation remains weak. The rise in debt-to-equity is especially important because it coincides with negative free cash flow, potentially making future investment and capital allocation more dependent on external financing.

Margin PressureThe decline in gross margin signals pressure on the economics of sales, whether from cost, pricing, or product mix factors identified in the financial assessment. If sustained, weaker margins can limit earnings growth from rising revenue and reduce the benefit of operating scale.

Rossari Biotech Ltd News

Rossari Biotech Sets July 20 Investor Call on Q1 FY27 Results

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has issued an update. Rossari Biotech Ltd has scheduled an earnings conference...

3M ago

Rossari Biotech Publishes AGM Notice and Details of E-Voting Facility

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an update. Rossari Biotech has notified exchanges that it has...

3M ago

Rossari Biotech sets July 20 virtual AGM, proposes dividend and related-party approvals

An announcement from Rossari Biotech Ltd ( ($IN:ROSSARI) ) is now available. Rossari Biotech Ltd has scheduled its...

3M ago

Rossari Biotech Releases Integrated Sustainability Report for FY 2025-26

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has issued an announcement. Rossari Biotech Limited has released its Business Responsibility...

3M ago

Rossari Biotech dispatches AGM, annual report access details to non-email shareholders

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an update. Rossari Biotech has informed stock exchanges that it...

3M ago

Rossari Biotech Faces Court Challenge to Arbitration Award in Unitop Acquisition Dispute

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an announcement. Rossari Biotech has disclosed that the sellers of...

4M ago

Rossari Biotech Publishes FY26 Audited Results Extracts in Financial Dailies

Rossari Biotech Ltd ( ($IN:ROSSARI) ) just unveiled an update. Rossari Biotech Ltd has announced that it has...

5M ago

Rossari Biotech posts record Q4 and steady FY26 growth despite margin pressure

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has shared an announcement. Rossari Biotech reported its highest-ever quarterly performance in...

5M ago

Rossari Biotech Reschedules Subsidiaries’ Capacity Expansion in Phased Rollout

Rossari Biotech Ltd ( ($IN:ROSSARI) ) has issued an update. Rossari Biotech has announced that its material subsidiaries,...

5M ago

Rossari Biotech to Host Q4 FY26 Earnings Call on April 28

The latest update is out from Rossari Biotech Ltd ( ($IN:ROSSARI) ). Rossari Biotech Ltd has scheduled an...

5M ago

ROSSARI FAQ

What was Rossari Biotech Ltd’s price range in the past 12 months?

Rossari Biotech Ltd lowest stock price was ₹372.90 and its highest was ₹690.90 in the past 12 months.

What is Rossari Biotech Ltd’s market cap?

Rossari Biotech Ltd’s market cap is ₹23.11B.

When is Rossari Biotech Ltd’s upcoming earnings report date?

Rossari Biotech Ltd’s upcoming earnings report date is Oct 19, 2026 which is in 16 days.

How were Rossari Biotech Ltd’s earnings last quarter?

Rossari Biotech Ltd released its earnings results on Jul 18, 2026. The company reported ₹6.4 earnings per share for the quarter, missing the consensus estimate of ₹8.8 by -₹2.4.

Is Rossari Biotech Ltd overvalued?

According to Wall Street analysts Rossari Biotech Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rossari Biotech Ltd pay dividends?

Rossari Biotech Ltd pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.12%. See more information on Rossari Biotech Ltd dividends here

What is Rossari Biotech Ltd’s EPS estimate?

Rossari Biotech Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rossari Biotech Ltd have?

Rossari Biotech Ltd has 55,394,115 shares outstanding.

What happened to Rossari Biotech Ltd’s price movement after its last earnings report?

Rossari Biotech Ltd reported an EPS of ₹6.4 in its last earnings report, missing expectations of ₹8.8. Following the earnings report the stock price went down -1.947%.

Which hedge fund is a major shareholder of Rossari Biotech Ltd?

Currently, no hedge funds are holding shares in IN:ROSSARI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Rossari Biotech Ltd

Rossari Biotech Limited, an India-based company, is a global manufacturer and distributor of specialized chemical products. Its diverse offerings cater to numerous industries, including ingredients for soaps and detergents, formulations for inks, paints, and coatings, materials for ceramics and tiles, solutions for pulp and paper production, components for cement, and water treatment compounds. The company also provides a broad spectrum of textile processing chemicals, supporting various fabrics like cotton, polyester, acrylic, wool, silk, and nylon, alongside functional finishes, denim treatments, and eco-friendly options. Additionally, Rossari Biotech develops pet grooming essentials such as natural shampoos, powders, deodorants, sprays, creams, and floor cleaners, marketed under brands like Lozalo, Hunger Fills, and Sniffy. Its portfolio extends to poultry nutrition products, encompassing vitamin-mineral blends, toxin binders, enzyme preparations, liquid nutraceuticals, and herbal supplements. Founded in 2003, the firm, initially named Rossari Labtech, rebranded to Rossari Biotech Limited in December of the same year and is headquartered in Mumbai, India.